These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20380636)

  • 1. Perspectives for novel mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy.
    Silva Dde O
    Anticancer Agents Med Chem; 2010 May; 10(4):312-23. PubMed ID: 20380636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds.
    Morais TS; Valente A; Tomaz AI; Marques F; Garcia MH
    Future Med Chem; 2016 Apr; 8(5):527-44. PubMed ID: 27096164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?
    Nardon C; Brustolin L; Fregona D
    Future Med Chem; 2016; 8(2):211-26. PubMed ID: 26807601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruthenium-based chemotherapeutics: are they ready for prime time?
    Antonarakis ES; Emadi A
    Cancer Chemother Pharmacol; 2010 May; 66(1):1-9. PubMed ID: 20213076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.
    Bergamo A; Gaiddon C; Schellens JH; Beijnen JH; Sava G
    J Inorg Biochem; 2012 Jan; 106(1):90-9. PubMed ID: 22112845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruthenium complexes can target determinants of tumour malignancy.
    Bergamo A; Sava G
    Dalton Trans; 2007 Apr; (13):1267-72. PubMed ID: 17372640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances on Dark and Light-Activated Cytotoxity of Imidazole-Containing Ruthenium Complexes.
    Liu P; Jia J; Zhao Y; Wang KZ
    Mini Rev Med Chem; 2016; 16(4):272-89. PubMed ID: 26586123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruthenium antimetastatic agents.
    Alessio E; Mestroni G; Bergamo A; Sava G
    Curr Top Med Chem; 2004; 4(15):1525-35. PubMed ID: 15579094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruthenium anticancer agent KP1019 binds more tightly than NAMI-A to tRNA
    Dwyer BG; Johnson E; Cazares E; McFarlane Holman KL; Kirk SR
    J Inorg Biochem; 2018 May; 182():177-183. PubMed ID: 29501978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.
    Rademaker-Lakhai JM; van den Bongard D; Pluim D; Beijnen JH; Schellens JH
    Clin Cancer Res; 2004 Jun; 10(11):3717-27. PubMed ID: 15173078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy.
    Abid M; Shamsi F; Azam A
    Mini Rev Med Chem; 2016; 16(10):772-86. PubMed ID: 26423699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
    Brabec V; Nováková O
    Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin.
    Groessl M; Zava O; Dyson PJ
    Metallomics; 2011 Jun; 3(6):591-9. PubMed ID: 21399784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Deceptively Similar Ruthenium(III) Drug Candidates KP1019 and NAMI-A Have Different Actions. What Did We Learn in the Past 30 Years?
    Alessio E; Messori L
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
    Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
    J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of KP1019 and NAMI-A in tumour-mimetic environments.
    Gransbury GK; Kappen P; Glover CJ; Hughes JN; Levina A; Lay PA; Musgrave IF; Harris HH
    Metallomics; 2016 Aug; 8(8):762-73. PubMed ID: 27460862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.
    Bergamo A; Sava G
    Dalton Trans; 2011 Aug; 40(31):7817-23. PubMed ID: 21629963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
    Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
    Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells.
    Bergamo A; Zorzet S; Gava B; Sorc A; Alessio E; Iengo E; Sava G
    Anticancer Drugs; 2000 Sep; 11(8):665-72. PubMed ID: 11081461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer ruthenium(III) complex KP1019 interferes with ATP-dependent Ca2+ translocation by sarco-endoplasmic reticulum Ca2+-ATPase (SERCA).
    Sadafi FZ; Massai L; Bartolommei G; Moncelli MR; Messori L; Tadini-Buoninsegni F
    ChemMedChem; 2014 Aug; 9(8):1660-4. PubMed ID: 24920093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.